We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials
News

Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials

Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials
News

Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProBioGen has announced that an investigational vaccine against Ebola virus disease, produced on its proprietary, continuous muscovy duck AGE1.CR.pIX® cell line, has proceeded into clinical trials at the Jenner Institute, Oxford University, UK.

The vaccine candidate, a modified vaccinia Ankara (MVA) Ebola Zaire vaccine (MVA EBOZ) was produced by Emergent BioSolutions at a 200 liter scale to supply the Phase 1 clinical trial.

Professor Adrian Hill, Director from Oxford’s Jenner Institute commented: “Production of the first ever batch of MVA for a clinical trial using a cell line is a milestone in the development of this important vaccine technology. This new process, which will allow very large scale production, will be of value not only for Ebola prevention, but also for a wide range of other disease indications including malaria and tuberculosis vaccination.”

Dr Volker Sandig, ProBioGen’s Chief Scientific Officer, added: “Our AGE1.CR® manufacturing platform offers shorter response times, full industrial bioreactor scalability and therefore much greater flexibility, compared to traditional vaccine production processes depending on embryonated chicken eggs. It is very satisfying to see that our broadly applicable vaccine production platform is instrumental to efficiently supply urgently needed human vaccines available to patients world-wide.”

Advertisement